Deep learning-enhanced peritumoral radiomics predicts early recurrence after hepatocellular carcinoma ablation: A two-center study

doi:10.4251/wjgo.122464

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 10

This Article

(2)

(0)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Oct 15, 2026; 18(10): 122464
Published online Oct 15, 2026. doi: 10.4251/wjgo.122464

Table 1 Clinical and image characteristics of patients in different cohorts, n (%)

Item	Training (n = 155)	Internal validation (n = 67)	External validation (n = 74)	P value
Tumor size (cm)	2.91 (1.64)	2.68 (0.98)	2.70 (1.18)	0.408
Age (years)	57.9 (11.1)	58.8 (12.4)	58.6 (12.0)	0.853
Sex				0.833
Female	30 (19.4)	13 (19.4)	12 (16.2)
Male	125 (80.6)	54 (80.6)	62 (83.8)
HBV				0.435
Positive	53 (34.2)	29 (43.3)	27 (36.5)
Negative	102 (65.8)	38 (56.7)	47 (63.5)
Cirrhosis				0.261
Positive	28 (18.1)	17 (25.4)	11 (14.9)
Negative	127 (81.9)	50 (74.6)	63 (85.1)
N				0.949
< 1.8	64 (41.3)	24 (35.8)	28 (37.8)
1.8-6.3	89 (57.4)	42 (62.7)	45 (60.8)
> 6.3	2 (1.29)	1 (1.49)	1 (1.35)
L				0.583
≥ 1.1	67 (43.2)	31 (46.3)	28 (37.8)
< 1.1	88 (56.8)	36 (53.7)	46 (62.2)
ALT				0.085
≤ 50	115 (74.2)	47 (70.1)	63 (85.1)
> 50	40 (25.8)	20 (29.9)	11 (14.9)
AST				0.347
> 40	68 (43.9)	27 (40.3)	25 (33.8)
≤ 40	87 (56.1)	40 (59.7)	49 (66.2)
GGT				0.805
≤ 60	85 (54.8)	38 (56.7)	38 (51.4)
> 60	70 (45.2)	29 (43.3)	36 (48.6)
GLB				0.444
≤ 35	122 (78.7)	52 (77.6)	63 (85.1)
> 35	33 (21.3)	15 (22.4)	11 (14.9)
HbsAg				0.757
Positive	28 (18.1)	13 (19.4)	11 (14.9)
Negative	127 (81.9)	54 (80.6)	63 (85.1)
AFP				0.167
< 40	39 (25.2)	20 (29.9)	15 (20.3)
40-400	92 (59.4)	30 (44.8)	47 (63.5)
> 400	24 (15.5)	17 (25.4)	12 (16.2)
Np				0.933
< 1.8	31 (20.0)	10 (14.9)	14 (18.9)
1.8-6.3	70 (45.2)	33 (49.3)	34 (45.9)
> 6.3	54 (34.8)	24 (35.8)	26 (35.1)
Lp				0.968
≥ 1.1	101 (65.2)	43 (64.2)	49 (66.2)
< 1.1	54 (34.8)	24 (35.8)	25 (33.8)
ALTp				0.504
≤ 50	33 (21.3)	13 (19.4)	20 (27.0)
> 50	122 (78.7)	54 (80.6)	54 (73.0)
ASTp				0.483
> 40	136 (87.7)	62 (92.5)	64 (86.5)
≤ 40	19 (12.3)	5 (7.46)	10 (13.5)
GGTp				0.965
≤ 60	92 (59.4)	41 (61.2)	44 (59.5)
> 60	63 (40.6)	26 (38.8)	30 (40.5)
GLBp				0.972
≤ 35	115 (74.2)	50 (74.6)	54 (73.0)
> 35	40 (25.8)	17 (25.4)	20 (27.0)
Capsule appearance				0.136
Positive	97 (62.6)	39 (58.2)	36 (48.6)
Negative	58 (37.4)	28 (41.8)	38 (51.4)
Intratumor vascularity				0.811
Positive	60 (38.7)	28 (41.8)	27 (36.5)
Negative	95 (61.3)	39 (58.2)	47 (63.5)
Tumor growth patter				0.612
Positive	113 (72.9)	53 (79.1)	56 (75.7)
Negative	42 (27.1)	14 (20.9)	18 (24.3)
Intratumor necrosis				0.781
Positive	92 (59.4)	39 (58.2)	47 (63.5)
Negative	63 (40.6)	28 (41.8)	27 (36.5)
PACE				0.607
Positive	123 (79.4)	54 (80.6)	55 (74.3)
Negative	32 (20.6)	13 (19.4)	19 (25.7)
Tumor margin				0.648
Positive	100 (64.5)	39 (58.2)	45 (60.8)
Negative	55 (35.5)	28 (41.8)	29 (39.2)
Ablation method				0398
RFA	44 (28.4)	21 (31.3)	16 (21.6)
MWA	111 (71.6)	46 (68.7)	58 (7.4)
PFS				0.659
Absent	93 (60.0)	41 (61.2)	49 (66.2)
Present	62 (40.0)	26 (38.8)	25 (33.8)

HBV: Hepatitis B virus; N: Neutrophil; L: Lymphocyte; ALT: Alanine transferase; AST: Aspartate transferase; GGT: Gammaglutamyl transferase; GLB: Globulin; HbsAg: Hepatitis B surface antigen; AFP: Alpha fetoprotein; Np: Postoperative neutrophil; Lp: Postoperative lymphocyte; ALTp: Postoperative alanine transferase; ASTp: Postoperative aspartate transferase; GGTp: Postoperative gammaglutamyl transferase; GLBp: Postoperative globulin; PACE: Peritumoral arterial contrast enhancement; RFA: Radiofrequency ablation; MWA: Microwave ablation; PFS: Progression-free survival.

Full Size Table

Citation: Li YH, Yao L, Qian GX, Lei XD, Tang ZQ, Guo BY, Du R, Zhu Y, Jia WD. Deep learning-enhanced peritumoral radiomics predicts early recurrence after hepatocellular carcinoma ablation: A two-center study. World J Gastrointest Oncol 2026; 18(10): 122464
URL: https://www.wjgnet.com/1948-5204/full/v18/i10/122464.htm
DOI: https://dx.doi.org/10.4251/wjgo.122464

Li YH, Yao L, Qian GX, Lei XD, Tang ZQ, Guo BY, Du R, Zhu Y, Jia WD. Deep learning-enhanced peritumoral radiomics predicts early recurrence after hepatocellular carcinoma ablation: A two-center study. World J Gastrointest Oncol 2026; 18(10): 122464 [DOI: 10.4251/wjgo.122464]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.